New drug cocktail targets tough lung cancer before and after surgery
NCT ID NCT07472478
First seen Mar 19, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests whether giving a combination of targeted drugs and chemotherapy before and after surgery can improve outcomes for people with a specific genetic subtype of lung cancer (KRAS G12C mutation). About 32 adults with stage IB to IIIB lung cancer that can be removed will receive the drugs glesorasib, ivonescimab, and chemotherapy. The main goal is to see how many patients have no cancer cells left in their removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.